Skip to main content
Equibles
FDMT logo

FDMT · 4D Molecular Therapeutics, Inc.

Track FDMT — free

Use FDMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FDMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.17 -0.32 (-2.37%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$950.61M
Shares
72.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.17 Open$13.69 Day$12.94–14.02 52W close$6.60–16.76 Avg vol 30d931K Short int12.1M · 16.7% float · 8.2d Short vol65% Last earningsAug 8, 2024 DataDec 2020–Sep 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$92.01M
Trailing 12 months
Net income (TTM)
−$179.18M
Trailing 12 months
Revenue growth YoY
+25,106.7%
Year over year
Operating margin
-214.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$341.75M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.6%
Year over year · more shares
Price change (1Y)
+86.3%
Trailing year
Short interest
16.7%
Latest settlement · 8.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +30%
above
Price vs 50-day avg +4%
above
RSI (14) 45
neutral
MACD trend Negative
52-week position 65%
mid-range
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +53%
trailing
YTD return +76%
this year
Relative strength +35%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.72% of float · ▼ -1.8% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Strong
Revenue growth +230195%
Y/Y
EPS growth +19%
Y/Y
Free cash flow $-109.6M
Quant / Vol
risk profile
Very High
Volatility 80%
annualized · 1-yr
Max drawdown −41%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+30% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
65% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.72% of float · ▼ -1.8% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $13 · 65% Range high $17
vs 200-day avg +30% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FDMT
4D Molecular Therapeutics, Inc.
this stock
$950.61M +75.6% +230194.6% — 16.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
159
% held
81.1%
Net QoQ
+7.7M sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
176
View
Short & Settlement
Short Interest Falling
Shares short
12.1M
Days to cover
8.2d
Change
-220.4K sh
View
Short Volume
Short vol %
65%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
217
Value
$2.5K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
29.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$85.2M
Net income (FY)
$-140.1M
EPS diluted
$-2.42
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
17
View
Proposed Sales
Value
$79.7K
Shares
6.5K
Filed
Aug 17, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View

Performance

5D 20D 120D MTD YTD
FDMT -10.4% +13.1% +53.0% -6.7% +75.6%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -9.3% +14.8% +35.1% -6.3% +63.5%
Key facts CIK 1650648 CUSIP 35104E100 13F (30d) 64 filings 64 filers Visit website Investor relations